MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtha.2023.01.001

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2023

von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

Pagliari Maria Teresa, Budde Ulrich, Baronciani Luciano, Eshghi Peyman, Ahmadinejad Minoo, Badiee Zahra, Baghaipour Mohammad-Reza, Benítez Hidalgo Olga, Biguzzi Eugenia, Bodó Imre, Castaman Giancarlo, Goudemand Jenny, Karimi Mehran, Keikhaei Bijan, Lassila Riitta, Leebeek Frank W G, Lopez Fernandez Maria Fernanda, Marino Renato, Oldenburg Johannes, Peake Ian, Santoro Cristina, Schneppenheim Reinhard, Tiede Andreas, Toogeh Gholamreza, Tosetto Alberto, Trossaert Marc, Yadegari Hamideh, Zetterberg Eva M K, Mannucci Pier Mannuccio, Federici Augusto B, Eikenboom Jeroen, Peyvandi Flora

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Type 3 von Willebrand disease (VWD) is the most severe form of this disease owing to the almost complete deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived products containing VWF or recombinant VWF rarely cause the development of alloantibodies against VWF that may be accompanied by anaphylactic reactions.

OBJECTIVE

The objective of this study was to assess the prevalence of anti-VWF alloantibodies in subjects with type 3 VWD enrolled in the 3WINTERS-IPS.

METHODS

An indirect in-house enzyme-linked immunosorbent assay has been used to test all the alloantibodies against VWF. Neutralizing antibodies (inhibitors) have been tested with a Bethesda-based method by using a VWF collagen binding (VWF:CB) assay. Samples positive for anti-VWF antibodies were further tested with Bethesda-based methods by using the semiautomated gain-of-function glycoprotein-Ib binding (VWF:GPIbM) and a VWF antigen (VWF:Ag) enzyme-linked immunosorbent assay.

RESULTS

In total, 18 of the 213 (8.4%) subjects tested positive for anti-VWF antibodies and 13 of 213 (6%) had VWF:CB inhibitors. These 13 were among the 18 with anti-VWF antibodies. Of the 5 without VWF:CB inhibitors, 3 had non-neutralizing antibodies, 1 only inhibitor against VWF:GPIbM, and one could not be tested further. Ten of the 13 subjects with VWF:CB inhibitors also had VWF:GPIbM inhibitors, 6 of whom also had VWF:Ag inhibitors. Subjects with inhibitors were homozygous for VWF null alleles (11/14), homozygous for a missense variant (1/14), or partially characterized (2/14).

CONCLUSIONS

Anti-VWF antibodies were found in 8.4% of subjects with type 3 VWD, whereas neutralizing VWF inhibitors were found in 6%, mainly in subjects homozygous for VWF null alleles. Because inhibitors may be directed toward different VWF epitopes, their detection is dependent on the assay used.

Для цитирования: Pagliari Maria Teresa, Budde Ulrich, Baronciani Luciano, Eshghi Peyman, Ahmadinejad Minoo, Badiee Zahra, Baghaipour Mohammad-Reza, Benítez Hidalgo Olga, Biguzzi Eugenia, Bodó Imre, Castaman Giancarlo, Goudemand Jenny, Karimi Mehran, Keikhaei Bijan, Lassila Riitta, Leebeek Frank W G, Lopez Fernandez Maria Fernanda, Marino Renato, Oldenburg Johannes, Peake Ian, Santoro Cristina, Schneppenheim Reinhard, Tiede Andreas, Toogeh Gholamreza, Tosetto Alberto, Trossaert Marc, Yadegari Hamideh, Zetterberg Eva M K, Mannucci Pier Mannuccio, Federici Augusto B, Eikenboom Jeroen, Peyvandi Flora. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.. Journal of thrombosis and haemostasis : JTH. 2023. DOI: 10.1016/j.jtha.2023.01.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.